Skip to main content

Table 2 Association between clinicopathologic features and KPNA2 protein expression

From: Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer

KPNA2 expression
  n Negative Weak Positive p-value
Age (years)      0.746
  < 65 78 22 (28.2) 36 (46.2) 20(25.6)  
  ≥ 65 117 37 (31.6) 47 (40.2) 33 (28.2)  
Sex      0.665
 Male 83 25 (30.1) 33 (39.8) 25 (30.1)  
 Female 112 34 (30.4) 50 (44.6) 28 (25.0)  
Location      0.664
 Right 82 21(25.6) 37 (45.1) 24 (29.3)  
 Transverse 18 9 (50.0) 7 (38.9) 2 (11.1)  
 Descendent 18 5 (27.8) 7(38.9) 6 (33.3)  
 Left 77 25(32.5) 32 (41.6) 20 (26.0)  
AJCC stage      0.01*
 I 22 12 (54.5) 7 (31.8) 3 (13.6)  
 II 79 25 (31.6) 37 (46.8) 17 (21.5)  
 III 76 21 (27.6) 30 (39.5) 25 (32.9)  
 IV 18 1 (5.6) 8 (44.4) 9 (50.0)  
N stage      0.025*
 N0 104 40 (38.5) 45 (43.3) 19 (18.3)  
 N1 57 14 (24.6) 22 (38.6) 21 (36.8)  
 N2 34 6 (17.6) 15 (44.1) 13 (38.2)  
M stage      0.014*
 M0 177 58 (32.8) 75 (42.4) 44 (24.9)  
 M1 18 1 (5.6) 8 (44.4) 9 (50.0)  
T stage      0.018*
 T1 + T2 28 14 (50.0) 12 (42.9) 2 (7.1)  
 T3 + T4 167 46 (27.5) 71 (42.5) 50 (30.0)  
Differentiation      0.001*
 High 97 39 (40.2) 41 (42.3) 17 (17.5)  
 Moderate 68 13 (19.1) 33 (48.5) 22 (32.4)  
 Low 30 8 (26.7) 8 (26.7) 14 (46.7)  
Vascular invasion      0.604
 Yes 14 3 (21.4) 8 (57.1) 3 (21.4)  
 No 181 56 (30.9) 75 (41.4) 50 (27.6)  
Ki-67 expression      0.002*
 Negative 36 11 (30.6) 22 (61.1) 3 (8.3)  
 Positive 159 48 (30.2) 60 (37.8) 50 (31.4)  
  1. *p < 0.005 indicates a significant association between the variables